Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Drug

BEBT-908 Receives Conditional NMPA Approval for Relapsed/Refractory DLBCL

Fineline Cube Jul 4, 2025

Guangzhou BeBetter Medicine Technology Co., Ltd’s first-in-class HDAC/PI3Kα dual-targeted inhibitor BEBT-908 has received conditional approval...

Company Deals

Fosun Pharma Subsidiary Launches Co-Developed Biochemical Reagent with Siemens Healthineers

Fineline Cube Jul 4, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Diagnostics (Shanghai) Co.,...

Company Drug

CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment

Fineline Cube Jul 4, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...

Company Drug

Kanion Pharma and Space Peptides Submit IND for AI-Enabled CCR8 Peptide Inhibitor KYS2301

Fineline Cube Jul 4, 2025

Chinese partners Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) and Space Peptides jointly announced the...

Company Deals

CR Medical Holdings Partners with Shanghai Haohai Bio in Medical Aesthetics Sector

Fineline Cube Jul 4, 2025

China Resources Medical Holdings Company Limited has entered into a strategic partnership with Shanghai Haohai...

Company Deals Drug

Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China

Fineline Cube Jul 4, 2025

China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical...

Company Deals

AstraZeneca CEO Soriot Explores US Stock Listing Move, Potentially Impacting London Exchange

Fineline Cube Jul 3, 2025

AstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot is exploring plans to move the British pharmaceutical...

Company Drug

Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11

Fineline Cube Jul 3, 2025

China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice...

Company Drug

Dizal’s Sunvozertinib Receives FDA Accelerated Approval for EGFR Exon20ins NSCLC

Fineline Cube Jul 3, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that the U.S. Food and Drug Administration...

Company Drug

Servier’s Voranigo Approved for IDH-Mutant Diffuse Glioma in Beijing

Fineline Cube Jul 3, 2025

French firm Servier Pharmaceutical plc.’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2)...

Company Drug

Sichuan Biokin’s Iza-bren Meets Primary Endpoint in Phase III NPC Trial

Fineline Cube Jul 3, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its Phase III clinical study...

Company Drug

Genrix Bio Receives NMPA Clearance for GR1803 in Relapsed/Refractory Multiple Myeloma

Fineline Cube Jul 3, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that it has received clinical trial...

Company Drug

Simcere Pharma’s Suvemcitug Approved by China’s NMPA for Platinum-Resistant Ovarian Cancer

Fineline Cube Jul 3, 2025

China-based Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that it has received marketing approval...

Company Drug

China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment

Fineline Cube Jul 3, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial...

Company Deals

Sun-Novo Pharma Collaborates with LeKuang Huilin on STC007 for Post-Abdominal Surgery Pain

Fineline Cube Jul 3, 2025

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) this week entered into a technology...

Company Drug

AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion

Fineline Cube Jul 3, 2025

US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...

Company Drug

Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis

Fineline Cube Jul 3, 2025

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its...

Company Deals

XtalPi Completes Pre-Seed Investment in Foundry BioSciences to Advance AI-Driven Longevity Therapeutics

Fineline Cube Jul 3, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced the completion of a...

Company Drug

CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT

Fineline Cube Jul 3, 2025

China-based CANbridge Pharmaceuticals Inc., (HKG: 1228) announced that the first prescription of its Geruining (velaglucerase...

Company Drug

InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3

Fineline Cube Jul 3, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval...

Posts pagination

1 … 91 92 93 … 624

Recent updates

  • CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility
  • GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
  • Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play
  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility

Company

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

Company Medical Device

Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.